Certification in Specialty Pharmacy Exam - Preparation Course

Activity Description

Specialty pharmacy is the fastest growing segment of pharmacy practice today and will continue for the foreseeable future. Specialty pharmacy impacts only a small percent of the population; however, the diseases and drug therapies are very complex and require a higher level of knowledge compared to more traditional diseases and drug therapies. The Certified Specialty Pharmacist Credential is designed to validate your professional expertise, elevate the status of the specialty pharmacy profession, differentiate yourself in a competitive job market, position yourself for handling limited or exclusively distributed drugs, position yourself to better serve payer requirements, and protect the public by improving their health outcomes and reducing medication errors.

The CSP Exam Preparatory Course will cover aspects of Clinical, Fulfillment, Intake and Outcomes that might be expected on the exam. Join expert faculty as key aspects of specialty pharmacy and the specialty pharmacist’s role are discussed. Key topics include the fundamentals and considerations for the patient intake process, as well as fulfillment workflows, quality assurance and dispensing channels. Outcomes measures and standards are covered, and clinical modules review persistence and adherence, specialty drug classes, indications, interactions, and more.

Learning Objectives

The target audience for this activity includes pharmacists.

At the completion of Patient Intake, participants will be able to:
  • Outline and explain key considerations for the specialty pharmacist concerning the patient intake process.
  • Define and describe the central intake approach to the specialty pharmacy patient intake process.
  • Identify and distinguish the specific roles of pharmacists and pharmacy technicians in the patient intake process.
  • List and explain the fundamental steps of the patient intake process for specialty pharmaceuticals.
  • Identify and discuss specific business drivers as they relate to specialty pharmacy patients.
  • Compare and contrast key opportunities and challenges related to the specialty pharmacy patient intake process.
At the completion of Clinical Practice in Specialty Pharmacy, participants will be able to:
  • List the key components of the patient medical record related to the clinical management of the patient.
  • Define persistence and adherence.
  • Outline barriers to adherence.
  • Describe strategies to improve adherence.
  • Outline the various components of Risk Evaluation and Mitigation Strategies (REMS).
  • Identify the characteristics of Limited Distribution Drugs (LDD).
  • Discuss the specialty pharmacy role in assuring desired patient safety and patient outcomes.
At the completion of Clinical: Inflammatory Diseases, participants will be able to:
  • Identify different classes of medications, mechanisms of action, and indication used to treat auto-immune conditions
  • Identify standardized dosing schedules, route of administration, and storage considerations for medications used to treat auto-immune conditions
  • Discuss monitoring parameters, possible side effects, and complications associated with medications used to treat auto-immune conditions
At the completion of Clinical: Oncology, participants will be able to:
  • List dosing and indications for oral oncolytic therapies in oncology and hematology
  • Identify most commonly used therapies in practice and important counseling/monitoring parameters
  • Assess therapies for appropriateness based on drug-drug and drug-disease interactions
At the completion of Clinical: Hepatitis, participants will be able to:
  • Discuss the prevalence and diagnosis of hepatitis C
  • Describe the pharmacology of direct acting antivirals
  • Determine the appropriate treatment selection of a direct acting antiviral regimen
  • Identify common drug interactions with direct acting antivirals
At the completion of Clinical: Multiple Sclerosis, participants will be able to:
  • Differentiate the disease-modifying therapies (DMTs) for the treatment of multiple sclerosis (MS)
  • Identify both common and serious adverse effects, as well as significant drug/drug interactions for each DMT
  • Identify recommended monitoring parameters for each DMT, including Risk Evaluation and Mitigation Strategy (REMS) requirements
  • Recognize how each product is supplied and how to properly administer as well as store each DMT
At the completion of Clinical: HIV, participants will be able to:
  • Recognize medications from various classes of antiviral agents used to treat HIV
  • Discuss the mechanism of action for each class of medications
  • Explain recommended protocols and assess a treatment plan for clinical appropriateness
  • Discuss the limitations and considerations of various medications based on patient-specific characteristics
At the completion of Fulfillment, participants will be able to:
  • Define the Pharmacist role in specialty pharmaceutical fulfillment workflows
  • Describe the steps required to screen specialty pharmacy orders
  • Explain the importance of quality assurance in the specialty product fulfillment
  • Identify primary dispensing channels
  • Compare and contrast key opportunities and challenges in the specialty pharmaceuticals fulfillment process
At the completion of Outcomes, participants will be able to:
  • Define the three categories health outcomes measures
  • Describe the value of specialty pharmacy in health outcomes terms
  • Describe outcomes that specialty pharmacies can measure to demonstrate value
  • Describe the gold standards in measuring health outcomes
  • Discuss barriers to collecting optimal health outcomes data
  • Identify how payers are managing specialty pharmaceuticals


Erin Stack, PharmD (Patient Intake)
Supervising Pharmacist
Cottrill’s Specialty Pharmacy

King Vu, PharmD (Patient Intake)
Clinical Help Desk Pharmacist
Diplomat Pharmacy

Kevn McNamara, PharmD (Clinical)
Clinical Pharmacy Partners

April Jones, PharmD, CSP (Clinical)
Clinical Pharmacist, Specialty Pharmacy Services
Vanderbilt University Medical Center

Kellye D. Gibbs, PharmD, CSP (Clinical)
Clinical Pharmacist, Specialty Pharmacy Services
Vanderbilt University Rheumatology Clinic

Houston Wyatt, PharmD, CSP (Clinical)
Clinical Pharmacist, Specialty Pharmacy Services
Vanderbilt University Medical Center

Alicia Carver, PharmD, BCPS, CSP (Clinical)
Clinical Pharmacist, Specialty Pharmacy Services
Vanderbilt University Medical Center

Aimee Banks, PharmD, BCPS (Clinical)
Clinical Pharmacist
Multiple Sclerosis Clinic
Vanderbilt University Medical Center

Autumn D. Zuckerman PharmD, BCPS, AAHIVP, CSP (Clinical)
Program Director, Health Outcomes and Research
Vanderbilt Specialty Pharmacy

Stephen Lagano, MS, PE (Fulfillment)

Kanika Kapoor, PharmD, CSP (Outcomes)
Clinical Pharmacist
Diplomat Pharmacy


It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed in this activity. None of the speakers have any relevant commercial or financial relationships to disclose.

Please note: The information and views presented in this activity are those of the faculty through clinical practice and knowledge of the professional literature. Portions of this activity may include the use of drugs and/or devices for unlabeled indications, which should be considered experimental. Participants are advised to consult manufacturer product information and the professional literature, and use professional judgment in applying the presented information in patient-care activities.

CE Accreditation

Release Date: 02-06-2019
Expiration Date: 02-06-2022


This CE activity is jointly provided by ProCE, Inc. and NASP. ProCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Numbers 0221-9999-19-065-H04-P, 0221-9999-19-066-H01-P, 0221-9999-19-067-H01-P, 0221-9999-19-068-H01-P, 0221-9999-19-069-H01-P, 0221-9999-19-070-H01-P, 0221-9999-19-071-H04-P, 0221-9999-19-072-H04-P, and 0221-9999-19-073-H01-P have been assigned to these knowledge-based home-study CE activities (initial release date 02-06-19). These activities (9 individual activities) are approved for a maximum of 6.3 total contact hours (0.63 CEU) in states that recognize ACPE providers. Completion of the evaluations and the post-tests with a score of 70% or higher are required to receive CE credit. No partial credit will be given.


No external support has been received for this activity.

The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.